Abivax SA ADR (ABVX)

Currency in USD
144.65
+12.09(+9.12%)
Closed·
144.17-0.48(-0.33%)
·
ABVX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
137.63146.68
52 wk Range
7.70148.83
Key Statistics
Prev. Close
132.56
Open
138.87
Day's Range
137.63-146.68
52 wk Range
7.7-148.83
Volume
4.02M
Average Volume (3m)
2.01M
1-Year Change
1,717.2111%
Book Value / Share
6.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABVX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
160.09
Upside
+10.67%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Abivax SA ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 160.09
(+10.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Buy155.00+7.16%135.00MaintainJul 02, 2026
Citizens
Buy187.00+29.28%-MaintainJul 01, 2026
Jefferies
Buy158.00+9.23%108.00UpgradeJun 30, 2026
Guggenheim
Buy175.00+20.98%-MaintainJun 30, 2026
BTIG
Buy175.00+20.98%150.00MaintainJun 30, 2026

Earnings

Latest Release
May 22, 2026
EPS / Forecast
-0.71 / -0.60
Revenue / Forecast
1.51M / --
EPS Revisions
Last 90 days

ABVX Income Statement

Compare ABVX to Peers and Sector

Metrics to compare
ABVX
Peers
Sector
Relationship
P/E Ratio
−32.8x−3.2x−0.4x
PEG Ratio
0.57−0.150.00
Price/Book
25.4x0.1x2.6x
Price / LTM Sales
2,214.3x22.5x3.0x
Upside (Analyst Target)
10.6%194.1%50.7%
Fair Value Upside
Unlock−2.3%6.5%Unlock

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
13.98M17.55%1.85B
Other Institutional Investors
108.46M82.45%14.38B
Public Companies & Retail Investors
0.000.00%0.00
Total
122.45M100.00%16.23B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
UBS Asset Management AG9.76%7,774,9991,030,654
Darwin Global Management Limited9.70%7,728,6721,024,513

People Also Watch

18.470
ERAS
+3.07%
135.00
ABVX
+5.63%
29.46
TNGX
+2.54%
3.840
FULC
+5.49%
117.30
SOIT
+4.97%

FAQ

What Is the Abivax ADR (ABVX) Stock Price Today?

The Abivax ADR stock price today is 144.65 USD.

What Stock Exchange Does Abivax ADR Trade On?

Abivax ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Abivax ADR?

The stock symbol for Abivax ADR is "ABVX."

What Is the Abivax ADR Market Cap?

As of today, Abivax ADR market cap is 12.38B USD.

What Is Abivax ADR's Earnings Per Share (TTM)?

The Abivax ADR EPS (TTM) is -4.52.

When Is the Next Abivax ADR Earnings Date?

Abivax ADR will release its next earnings report on Sep 21, 2026.

From a Technical Analysis Perspective, Is ABVX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Abivax ADR Stock Split?

Abivax ADR has split 0 times.

How Many Employees Does Abivax ADR Have?

Abivax ADR has 80 employees.

What is the current trading status of Abivax ADR (ABVX)?

As of Jul 03, 2026, Abivax ADR (ABVX) is trading at a price of 144.65 USD, with a previous close of 132.56 USD. The stock has fluctuated within a day range of 137.63 USD to 146.68 USD, while its 52-week range spans from 7.70 USD to 148.83 USD.

What Is Abivax ADR (ABVX) Price Target According to Analysts?

The average 12-month price target for Abivax ADR is 160.09 USD, with a high estimate of 187 USD and a low estimate of 132 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +10.67% Upside potential.

What Is the ABVX After Hours Price?

ABVX's last after hours stock price is 144.17 USD, the stock has decreased by -0.48, or -0.33%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.